Screening of Anti‐Postmenopausal Osteoporosis Active Components With ESR2 Targeting Affinity in Dioscoreae Rhizoma Based on Affinity Ultrafiltration‐UPLC‐QE‐Orbitrap‐MS
Phytochemical Analysis · 2025
DOI: 10.1002/pca.70034 ↗Kurz gefasst
Fachartikel in der Zeitschrift Phytochemical Analysis, 2025. Verfasst von Wanjie Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Jilin Ginseng Academy, Changchun University of Chinese Medicine, Changchun, China. Hauptthemen laut MEDLINE: Dioscorea, Rhizome, Osteoporosis, Postmenopausal, Estrogen Receptor beta. Die Arbeit nennt 38 Literaturangaben. Gefördert von: Hebei Provincial Natural Science Foundation of China, National Natural Science Foundation of China, Jilin Province Development and Reform Commission.
Abstract (Originalsprache)
Background
Dioscoreae Rhizoma (DR) is a plant recognized for its dual medicinal and edible applications, exhibiting notable therapeutic efficacy, particularly in the treatment of postmenopausal osteoporosis (PMOP) associated with estrogen deficiency.
Objective
This study sought to systematically identify bioactive compounds present in DR that interact with estrogen receptor β (ESR2) and employ affinity ultrafiltration in conjunction with UPLC‐QE‐Orbitrap‐MS to find possible therapy options for PMOP.
Methods
In this study, a C18 column was employed to fractionate the DR extract into distinct fractions, and the optimal active site in DR was identified based on its osteoprotegerin (OPG) content in MC3T3‐E1 cells. To identify the DR components exhibiting high binding affinity for ESR2, affinity ultrafiltration coupled with UPLC‐QE‐Orbitrap‐MS was utilized. These findings were further corroborated through molecular docking and molecular dynamics simulations. To further validate the osteogenic effects of the identified compounds, CCK‐8 proliferation assays, along with OPG and alkaline phosphatase (ALP) activity assays, were employed.
Results
The 30% DR fraction demonstrated significant anti‐PMOP activity. Acacetin, Adenosine, and Procyanidin B2 are recognized as the principal active constituents responsible for the anti‐PMOP effects of DR.
Conclusion
This study introduces a comprehensive approach combining affinity ultrafiltration with UPLC‐QE‐Orbitrap‐MS and molecular docking to efficiently identify ESR2‐targeted therapeutic compounds for PMOP in DR. The findings offer both theoretical and empirical foundations for the advancement of novel therapeutic strategies for PMOP.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Jilin Ginseng Academy, Changchun University of Chinese Medicine, Changchun, China.
- School of Pharmaceutical Sciences, Quality Evaluation and Standardization Hebei Province Engineering Research Center of Traditional Chinese Medicine, Hebei University of Chinese Medicine, Shijiazhuang, China.
Förderung
- Hebei Provincial Natural Science Foundation of China
- National Natural Science Foundation of China
- Jilin Province Development and Reform Commission
- Natural Science Foundation of Hebei Province
Zitieren
APA
Liu, W., Yang, K., Li, Y., Li, Y., Wang, S., Yang, B., Feng, W., Lv, J., & Sun, J. (2025). Screening of Anti‐Postmenopausal Osteoporosis Active Components With ESR2 Targeting Affinity in Dioscoreae Rhizoma Based on Affinity Ultrafiltration‐UPLC‐QE‐Orbitrap‐MS. Phytochemical Analysis. https://doi.org/10.1002/pca.70034
Vancouver
Liu W, Yang K, Li Y, Li Y, Wang S, Yang B, et al. Screening of Anti‐Postmenopausal Osteoporosis Active Components With ESR2 Targeting Affinity in Dioscoreae Rhizoma Based on Affinity Ultrafiltration‐UPLC‐QE‐Orbitrap‐MS. Phytochemical Analysis. 2025. doi:10.1002/pca.70034
BibTeX
@article{Liu2025,
author = {Liu, Wanjie and Yang, Kunping and Li, Yishan and Li, Yawen and Wang, Shuo and Yang, Bing and Feng, Wei and Lv, Jingwei and Sun, Jiaming},
title = {Screening of Anti‐Postmenopausal Osteoporosis Active Components With ESR2 Targeting Affinity in Dioscoreae Rhizoma Based on Affinity Ultrafiltration‐UPLC‐QE‐Orbitrap‐MS},
journal = {Phytochemical Analysis},
year = {2025},
doi = {10.1002/pca.70034}
}
EUVIMED